Irene Pak

Statistics

Publications

Citations

197

H-Index

Active since

2015

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Irene Pak is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in hepatitis pharmacotherapy, antiviral drug resistance, and hepatitis c genotypes.

ORCID

Publications per year

2015–2022

Publications

Susceptibilities of Genotype 1a, 1b, and 3 Hepatitis C Virus Variants to the NS5A Inhibitor Elbasvir

Rong Liu, Stephanie Curry, Patricia McMonagle et al. · Antimicrobial Agents and Chemotherapy · 2015 · 77 citations · Full text

Life Sciences, Infectious Diseases, Pharmacology +17

Acceptance of Simulated Adult Patients With Medicaid Insurance Seeking Care in a Cancer Hospital for a New Cancer Diagnosis

Victoria A. Marks, Walter Hsiang, James Nie et al. · JAMA Network Open · 2022 · 57 citations · Full text

Public Affairs, Health Policy, Oncology +17

P0891 : Resistance analysis of virologic failures in Hepatitis C genotype 1 infected patients treated with grazoprevir/elbasvir +/− ribavirin: The C-worthy study

Stuart Black, Irene Pak, Paul Ingravallo et al. · Journal of Hepatology · 2015 · 33 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

A Machine‐Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma

Rui Wang, Xiao Shao, Junying Zheng et al. · Clinical Pharmacology & Therapeutics · 2019 · 30 citations

Medicine, Immunology, Oncology +17

1–4 of 4